binimetinib

Summary

Name(s) Target Manufacturer Status
binimetinib MAP2K1, MAP2K2 Array BioPharma Investigational

Clinical Trials

Trial Drug Status Phase
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma [NCT01763164] Dacarbazine, binimetinib Recruiting Phase 3
Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma [NCT01909453] LGX818, Zelboraf, binimetinib Recruiting Phase 3
MEK162 for Patients With RAS/RAF/MEK Activated Tumors [NCT01885195] binimetinib Recruiting Phase 2
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma [NCT02159066] BGJ398, INC280, LEE011, LGX818, binimetinib, buparlisib Recruiting Phase 2
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma [NCT01820364] BGJ398, INC280, LEE011, LGX818, binimetinib, buparlisib Recruiting Phase 2
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma [NCT01781572] LEE011, binimetinib Recruiting Phase 1/Phase 2
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors [NCT01449058] BYL719, binimetinib Recruiting Phase 1/Phase 2
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma [NCT01801358] binimetinib, sotrastaurin Recruiting Phase 1/Phase 2
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors [NCT01543698] LEE011, LGX818, binimetinib Recruiting Phase 1/Phase 2
#
Collabrx_tagline

PLEASE READ

Dear Therapy Finder® User:

During the past two years we have witnessed an unprecedented upswing in research activity leading to the identification of increasing numbers of actionable biomarkers and several effective targeted treatments. To accommodate this dramatic increase in the number of relevant biomarkers, their interactions, and other patient attributes, we are developing a new application design, one that will be both easier to use and more relevant to practicing physicians and patients. This new system will unify many of the best features and key learnings from the Therapy Finders with those from our Genomic Variant Annotation™ (GVA) reporting system.

Until we complete the redesign of our Therapy Finders or offer substitute decision-support products, we are suspending the updating of the Therapy Finders appearing on the CollabRx website and other sites.

If you click through and decide to use the Colon Cancer, Lung Cancer, Melanoma or Metastatic Breast Cancer Therapy Finders, please do so with caution, as some of the data have not been updated since October 15, 2014.

CollabRx, Inc.
July 6, 2015